BiotechTube

Opnurasib + TNO155 + trametinib + cetuximab + tislelizumab

Phase 1/2Recruiting
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer

Conditions

Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation

Trial Timeline

Jun 24, 2026 → Sep 25, 2029

NCT ID
NCT07468071

About Opnurasib + TNO155 + trametinib + cetuximab + tislelizumab

Opnurasib + TNO155 + trametinib + cetuximab + tislelizumab is a phase 1/2 stage product being developed by Novartis for Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07468071. Target conditions include Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation.

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT07468071Phase 1/2Recruiting

Competing Products

20 competing products in Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer

See all competitors
ProductCompanyStageHype Score
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
52
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
52
NBTXR3NanobiotixPhase 1/2
36
Tadalafil + GemcitabineEli LillyPhase 1
33
SPYK04Chugai PharmaceuticalPhase 1
33
LUNA18 + CetuximabChugai PharmaceuticalPhase 1
33
Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
77
Trastuzumab Deruxtecan + Cisplatin + Carboplatin + Pembrolizumab + PemetrexedDaiichi SankyoPhase 3
77
T-DXd + Durvalumab + Cisplatin + Carboplatin + Pemetrexed + Volrustomig + RilvegostomigDaiichi SankyoPhase 1
33
ASP2998 + Pembrolizumab + Enfortumab Vedotin + CarboplatinAstellas PharmaPhase 1/2
41
zolbetuximabAstellas PharmaPre-clinical
23
enfortumab vedotin + pembrolizumabAstellas PharmaPhase 2
52
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
77
enfortumab vedotin (EV)Astellas PharmaPre-clinical
23
zolbetuximabAstellas PharmaPre-clinical
23
zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3
77
ASP3082Astellas PharmaPhase 2
52
zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + PlaceboAstellas PharmaPhase 3
77
ASP1948Astellas PharmaPhase 1
33
Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine )Sun PharmaceuticalPhase 2
52

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85